[
    "{\"step_by_step_thinking\": \"Based on the information provided in the documents, the best treatment option for cancer-associated thromboembolism is low-molecular-weight heparin (LMWH). Document [0] states that low-molecular-weight heparin remains the best treatment option for initial and long-term treatment of VTE in cancer patients. Document [2] also mentions that the results of clinical trials have demonstrated the safety and efficacy of bodyweight-adjusted subcutaneous low-molecular-weight heparin administered at home for patients with acute deep vein thrombosis, which is particularly attractive in patients with cancer. Therefore, the correct answer is A. LMW heparin.\", \"answer_choice\": \"A\"}"
]